PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.

Abstract:

:We attempted to develop a highly sensitive and specific method for the detection of circulating tumor DNA (ctDNA) using a digital PCR (dPCR) assay for PIK3CA mutations (i.e., H1047R, E545K, and E542K) in primary breast cancer patients. The sensitivity of the dPCR assay for the mutant alleles was examined using cell lines with PIK3CA mutations and proved to be 0.01 %. Serum samples were collected pre-operatively from 313 stage I-III breast cancer patients, of whom 110 were found to have PIK3CA mutant tumors. The serum samples from these patients with PIK3CA mutant tumors were subjected to the dPCR assay, and 25 (22.7 %) were found to be positive. No PIK3CA mutant ctDNA was detected in the serum samples of 50 healthy women and 30 breast cancer patients with PIK3CA non-mutant tumors. The patients with PIK3CA mutant ctDNA were dichotomized into mutant ctDNA-high (ctDNA(high)) and ctDNA-low (ctDNA(low)) groups based on the median. The ctDNA(high) patients exhibited significantly shorter recurrence-free survival (RFS; P = 0.0002) and overall survival rates (OS; P = 0.0048) compared to those exhibited by the combined ctDNA(low) patient and ctDNA-free patient group. Multivariate analysis revealed that ctDNA(high) status significantly predicted poor RFS and OS and did so independently of conventional histological parameters. These results suggest that dPCR is a highly sensitive and specific method for the detection of PIK3CA mutant ctDNA and that ctDNA(high) but not ctDNA(low) status is a significant and independent prognostic factor for primary breast cancer patients.

authors

Oshiro C,Kagara N,Naoi Y,Shimoda M,Shimomura A,Maruyama N,Shimazu K,Kim SJ,Noguchi S

doi

10.1007/s10549-015-3322-6

subject

Has Abstract

pub_date

2015-04-01 00:00:00

pages

299-307

issue

2

eissn

0167-6806

issn

1573-7217

journal_volume

150

pub_type

杂志文章
  • Accuracy of fine needle aspiration cytology (FNAC) of axillary lymph nodes as a triage test in breast cancer staging.

    abstract:INTRODUCTION:Axillary node fine needle aspiration cytology (FNAC) has the potential to triage women with operable breast cancer to initial nodal surgical procedure. Because of variability in the reported accuracy of this test its role and clinical utility in pre-operative staging remains controversial. METHODS:We retr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9355-0

    authors: Ciatto S,Brancato B,Risso G,Ambrogetti D,Bulgaresi P,Maddau C,Turco P,Houssami N

    更新日期:2007-05-01 00:00:00

  • Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin.

    abstract::Serum melatonin (MLT) levels have been reported to diminish significantly by the 5th and 6th decades of life as the incidence of breast cancer increases. Given MLT's anti-cancer activity, we hypothesize that age-related decline in pineal MLT production leads to enhanced breast cancer development and growth as women ag...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-0958-0

    authors: Hill SM,Cheng C,Yuan L,Mao L,Jockers R,Dauchy B,Frasch T,Blask DE

    更新日期:2011-05-01 00:00:00

  • Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years.

    abstract::Studies from Western countries have found evidence of a recent decline in breast cancer incidence rates in postmenopausal women, findings which have been hypothesized to reflect a reduced use of hormonal replacement therapy (HRT). We examined breast cancer incidence trends in Sweden between 1997 and 2007, a period cha...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0615-7

    authors: Lambe M,Wigertz A,Holmqvist M,Adolfsson J,Bardage C,Fornander T,Karlsson P,Odlind V,Persson I,Ahlgren J,Bergkvist L

    更新日期:2010-06-01 00:00:00

  • Association between thyroid gland diseases and breast cancer: a case-control study.

    abstract:BACKGROUND:At the present time, there is no consensus on the association between benign thyroid diseases and breast cancer (BC). Therefore, the aim of this study is to help shed some light on the association between hyperthyroidism, hypothyroidism, and thyroiditis and breast cancer risk. METHODS:Use of the Disease Ana...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05675-6

    authors: Bach L,Kostev K,Schiffmann L,Kalder M

    更新日期:2020-07-01 00:00:00

  • The influence of angiogenesis research on management of patients with breast cancer.

    abstract::The diagnosis and treatment of patients with breast cancer is beginning to be influenced by new ideas and discoveries emerging from the field of angiogenesis research. This field, pursued in the laboratory for more than 20 years, has in the past 5 years generated clinical applications. Some of these applications have ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00666033

    authors: Folkman J

    更新日期:1995-01-01 00:00:00

  • Type I insulin-like growth factor receptor function in breast cancer.

    abstract::Experimental evidence suggests an important role of the type I IGF receptor (IGF-IR) in breast cancer development. Breast tumors and breast cancer cell lines express the IGF-IR. IGF-IR levels are higher in cancer cells than in normal breast tissue or in benign mammary tumors. The ligands of the IGF-IR are potent mitog...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1005907101686

    authors: Surmacz E,Guvakova MA,Nolan MK,Nicosia RF,Sciacca L

    更新日期:1998-02-01 00:00:00

  • Incidence of invasive breast cancer in the presence of competing mortality: the Canadian National Breast Screening Study.

    abstract::Mortality due to causes other than breast cancer is a potential competing risk which may alter the incidence probability of breast cancer and as such should be taken into account in predictive modelling. We used data from the Canadian National Breast Screening Study (CNBSS), which consist of two randomized controlled ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2113-6

    authors: Taghipour S,Banjevic D,Fernandes J,Miller AB,Montgomery N,Harvey BJ,Jardine AK

    更新日期:2012-07-01 00:00:00

  • Targeting the EGF receptor in breast cancer treatment.

    abstract::Immunotoxins are a relatively new class of cytotoxic agents consisting of a catalytic toxin linked to an appropriate targeting ligand. The ligand directs the toxin to the surface of a tumor cell, whereupon the toxin enters the cell and catalytically inactivates the ribosome, thus disrupting protein synthesis and effec...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00666210

    authors: LeMaistre CF,Meneghetti C,Howes L,Osborne CK

    更新日期:1994-01-01 00:00:00

  • HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites.

    abstract:BACKGROUND:Several recent epidemiologic studies examined the association between breast cancer risk and an inherited, single-nucleotide polymorphism in the HER2 gene, codon 655 G to A, which leads to an amino acid substitution of Ile to Val. Results of previous studies have been mixed, with most studies showing no asso...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1024068525763

    authors: Millikan R,Eaton A,Worley K,Biscocho L,Hodgson E,Huang WY,Geradts J,Iacocca M,Cowan D,Conway K,Dressler L

    更新日期:2003-06-01 00:00:00

  • Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study.

    abstract:PURPOSE:Tobacco smoking is a risk factor in several cancers, yet its roles as a putative etiologic exposure or poor prognostic factor in breast cancer are less clear. Altered DNA methylation contributes to breast cancer development and may provide a mechanistic link between smoking and gene expression changes leading t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4178-8

    authors: Conway K,Edmiston SN,Parrish E,Bryant C,Tse CK,Swift-Scanlan T,McCullough LE,Kuan PF

    更新日期:2017-06-01 00:00:00

  • Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.

    abstract::Gene fusions have long been considered principally as the oncogenic events of hematologic malignancies, but have recently gained wide attention in solid tumors due to several milestone discoveries and the advancement of deep sequencing technologies. With the progress in deep sequencing studies of breast cancer transcr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-016-3876-y

    authors: Veeraraghavan J,Ma J,Hu Y,Wang XS

    更新日期:2016-07-01 00:00:00

  • Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

    abstract::Numerous studies have demonstrated that angiogenesis and in particular VEGF over-expression play an essential role in the progression and metastatic potential of breast cancer. Bevacizumab is a humanized recombinant monoclonal antibody that specifically blocks the binding of VEGF to high-affinity receptors and it has ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-009-0727-0

    authors: Valachis A,Polyzos NP,Patsopoulos NA,Georgoulias V,Mavroudis D,Mauri D

    更新日期:2010-07-01 00:00:00

  • Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

    abstract::Metformin may reduce the incidence of breast cancer and enhance response to neoadjuvant chemotherapy in diabetic women. This trial examined the effects of metformin on Ki67 and gene expression in primary breast cancer. Non-diabetic women with operable invasive breast cancer received pre-operative metformin. A pilot co...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s10549-011-1612-1

    authors: Hadad S,Iwamoto T,Jordan L,Purdie C,Bray S,Baker L,Jellema G,Deharo S,Hardie DG,Pusztai L,Moulder-Thompson S,Dewar JA,Thompson AM

    更新日期:2011-08-01 00:00:00

  • mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.

    abstract::Resistance of breast cancers to targeted hormone receptor (HR) or human epidermal growth factor receptor 2 (HER2) inhibitors often occurs through dysregulation of the phosphoinositide 3-kinase, protein kinase B/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Presently, no targeted therapies exist for breast...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2877-y

    authors: Wilson-Edell KA,Yevtushenko MA,Rothschild DE,Rogers AN,Benz CC

    更新日期:2014-04-01 00:00:00

  • Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines.

    abstract::We analyzed the p53 mutational status, mRNA and protein expression in 24 human breast carcinoma cell lines. Following measurement of their DNA content with flow cytometry, we ascertained the copy numbers of the centromere of chromosome 17 (cen17) and p53 with fluorescence in situ hybridization (FISH). A functional yea...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1023351717408

    authors: Concin N,Zeillinger C,Tong D,Stimpfl M,König M,Printz D,Stonek F,Schneeberger C,Hefler L,Kainz C,Leodolter S,Haas OA,Zeillinger R

    更新日期:2003-05-01 00:00:00

  • A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.

    abstract::To determine whether capecitabine schedule adaptation improves the tolerability of capecitabine-paclitaxel combination therapy for metastatic breast cancer (MBC), patients with anthracycline-pretreated HER2-negative MBC were randomized to either arm A (21-day cycles: capecitabine 1,000 mg/m(2) twice daily, days 1-14; ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-011-1776-8

    authors: Lortholary A,Hardy-Bessard AC,Bachelot T,de Rauglaudre G,Alexandre J,Bourgeois H,Jaubert D,Paraiso D,Largillier R

    更新日期:2012-01-01 00:00:00

  • CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.

    abstract::Overexpression of CD24 is an independent prognostic factor for breast cancer. Recently, two polymorphisms in the CD24 gene were linked to disease risk and progression in autoimmune diseases. Here, we evaluated the clinical relevance of these polymorphisms with respect to their potential to predict a pathologic complet...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-011-1759-9

    authors: Marmé F,Werft W,Walter A,Keller S,Wang X,Benner A,Burwinkel B,Sinn P,Hug S,Sohn C,Bretz N,Moldenhauer G,Rupp C,Rupp AK,Biakhov MY,Bottini A,Friedrichs K,Khailenko VA,Manikhas GM,Ruiz A,Sánchez-Rovira P,Santoro A

    更新日期:2012-04-01 00:00:00

  • Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs excisional biopsy and irradiation.

    abstract::Thirty-eight patients treated for primary breast cancer as part of a prospective randomized clinical trial were questioned retrospectively as to their psychosocial adaptation to treatment. Twenty patients had received mastectomy and eighteen had received excisional biopsy plus radiation of the intact breast. Aside fro...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF01807591

    authors: Schain W,Edwards BK,Gorrell CR,de Moss EV,Lippman ME,Gerber LH,Lichter AS

    更新日期:1983-01-01 00:00:00

  • William L. McGuire Memorial Symposium. Control of breast cancer cell growth by steroids and growth factors: interactions and mechanisms.

    abstract::Over the past two decades, the simple model for control of breast cancer growth involving one or two factors acting directly or indirectly via endocrine pathways has turned into a complex model implicating numerous interacting factors and the diverse cell populations constituting breast tumors. Current approaches to b...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00683193

    authors: Freiss G,Prébois C,Vignon F

    更新日期:1993-01-01 00:00:00

  • Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer.

    abstract::Neurofibromatosis type 1 (NF1) is a common dominant autosomal disorder caused by mutations in the NF1 gene. The main manifestations of NF1 are café-au-lait spots, neurofibromas, intertriginous freckling, Lisch nodules, and malignancy, including peripheral nerve sheath tumors, central nervous system gliomas, and a vari...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2538-6

    authors: Campos B,Balmaña J,Gardenyes J,Valenzuela I,Abad O,Fàbregas P,Volpini V,Díez O

    更新日期:2013-06-01 00:00:00

  • DNA-repair genetic polymorphisms and risk of breast cancer in Cyprus.

    abstract::The DNA repair pathway is known to play a role in the etiology of breast cancer. A number of studies have demonstrated that common germline variants in genes involved in the DNA repair pathway influence breast cancer risk. To assess whether alterations in DNA repair genes contribute to breast cancer, we genotyped 12 s...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0084-4

    authors: Loizidou MA,Michael T,Neuhausen SL,Newbold RF,Marcou Y,Kakouri E,Daniel M,Papadopoulos P,Malas S,Hadjisavvas A,Kyriacou K

    更新日期:2009-06-01 00:00:00

  • Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost.

    abstract::Many patients with metastatic breast cancer receive several types of chemotherapy, although it is recognized that there is a declining probability of response. A major problem confronts oncologists in deciding when to recommend to patients that no further chemotherapy should be given. To address this problem we have a...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006123721205

    authors: McLachlan SA,Pintilie M,Tannock IF

    更新日期:1999-04-01 00:00:00

  • Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo.

    abstract::The glycolytic phenotype is a widespread phenomenon in solid cancer forms, including breast cancer. Dichloroacetate (DCA) has recently been proposed as a novel and relatively non-toxic anti-cancer agent that can reverse the glycolytic phenotype in cancer cells through the inhibition of pyruvate dehydrogenase kinase. W...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0435-9

    authors: Sun RC,Fadia M,Dahlstrom JE,Parish CR,Board PG,Blackburn AC

    更新日期:2010-02-01 00:00:00

  • Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.

    abstract::A minority of early invasive breast cancers show a pattern of central necrosis and fibrosis (CNF). Previous studies have documented an adverse prognostic impact and association with other adverse pathological features, but its predictive importance for therapy selection is unknown. We examined the prognostic and predi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-009-0360-y

    authors: Maiorano E,Regan MM,Viale G,Mastropasqua MG,Colleoni M,Castiglione-Gertsch M,Price KN,Gelber RD,Goldhirsch A,Coates AS

    更新日期:2010-05-01 00:00:00

  • A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.

    abstract::Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experimen...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805721

    authors: Allegra JC,Woodcock TM,Richman SP,Bland KI,Wittliff JL

    更新日期:1982-01-01 00:00:00

  • Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.

    abstract::Oestrogen receptor (ER) negative breast cancers are more likely to achieve a pathological complete response (pCR) to neoadjuvant chemotherapy compared to those with ER positive tumours. ER positive tumours exhibit low proliferation and ER negative cancers high proliferation. The aim of this study was to determine to w...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0329-x

    authors: Jones RL,Salter J,A'Hern R,Nerurkar A,Parton M,Reis-Filho JS,Smith IE,Dowsett M

    更新日期:2010-01-01 00:00:00

  • New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth.

    abstract:PURPOSE:Combining molecular therapies with chemotherapy may offer an improved clinical outcome for chemoresistant tumours. Sphingosine-1-phosphate (S1P) receptor antagonist and sphingosine kinase 1 (SK1) inhibitor FTY720 (FTY) has promising anticancer properties, however, it causes systemic lymphopenia which impairs it...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4380-8

    authors: Alshaker H,Wang Q,Srivats S,Chao Y,Cooper C,Pchejetski D

    更新日期:2017-10-01 00:00:00

  • Is mammographic density differentially associated with breast cancer according to receptor status? A meta-analysis.

    abstract::Mammographic density (MD) is a strong marker of breast cancer risk, but it is debated whether the association holds, and is of a similar magnitude, for different subtypes of breast cancer defined by receptor status or gene expression profiles. A literature search conducted in June 2012 was used to identify all studies...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-012-2362-4

    authors: Antoni S,Sasco AJ,dos Santos Silva I,McCormack V

    更新日期:2013-01-01 00:00:00

  • Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing.

    abstract:PURPOSE:Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating side effect in cancer survivors. This study aimed to assess the characteristics of quantitative sensory testing (QST) and its correlation with patient-reported outcomes (PROs) in cancer patients with and without CIPN. METHODS:We conduc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-06079-2

    authors: Zhi WI,Baser RE,Kwon A,Chen C,Li SQ,Piulson L,Seluzicki C,Panageas KS,Harte SE,Mao JJ,Bao T

    更新日期:2021-01-28 00:00:00

  • Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype.

    abstract::Loss of heterozygosity (LOH) in loci of the 10q23 region that harbor the PTEN gene and mutations in the sequence of this gene have been found in several primary human tumors including breast carcinomas, suggesting that this gene could be implicated in their pathogenesis. We investigated allelic losses in microsatellit...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006273516976

    authors: Garcia JM,Silva JM,Dominguez G,Gonzalez R,Navarro A,Carretero L,Provencio M,España P,Bonilla F

    更新日期:1999-10-01 00:00:00